AMERCHOL CORPORATION – Trademark Portfolio
Entity Type: 03
AMERCHOL CORPORATION holds 21 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 19 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include OHLAN, MODULAN, SOLULAN, and ACETULAN. The owner is based in EDISON, NJ.
136 TALMADGE ROAD
EDISON, NJ 088184051
Showing of trademarks Trademarks
Trademark Classifications
AMERCHOL CORPORATION's trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does AMERCHOL CORPORATION have?
AMERCHOL CORPORATION has 21 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 abandoned, 16 cancelled.
What trademark classes does AMERCHOL CORPORATION file in?
AMERCHOL CORPORATION files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are AMERCHOL CORPORATION's most well-known trademarks?
AMERCHOL CORPORATION's registered trademark portfolio includes well-known marks such as OHLAN, MODULAN, SOLULAN, and ACETULAN. These are among 4 currently registered trademarks in the portfolio.
What is AMERCHOL CORPORATION's trademark registration success rate?
AMERCHOL CORPORATION has a 19% trademark registration rate, with 4 out of 21 resolved applications resulting in successful registration. Currently, 0 applications are pending review.